Pramipexole - Restless Leg Syndrome

You are here : Home > Formulary Search > Pramipexole - Restless Leg Syndrome

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green

Formulations :

Immediate release tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

SPC

Restrictions / Comments :

Important

Preferred

Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment

Documentation

Evidence Review

Restless leg syndrome - APC Paper - November 2018

PAD Profile

ChemicalSubstance :

Pramipexole

Indication :

Restless Leg Syndrome

Group Name :

Keywords :

dopamine agonists, non-ergot-derived dopamine receptor agonists

Brand Names Include :

Mirapexin

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Committee Recommendations (1)

07 Nov 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Pramipexole is recommended as a FIRST line option for the treatment of Restless Leg Syndrome, as per CKS guidance.

Link to CKS page - https://cks.nice.org.uk/restless-legs-syndrome

Other Indications

Below are listed other indications that Pramipexole is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Restless Leg Syndrome.